

جمهورية العراق وزارة التعليم العالي والبحث العلمي جامعة بابل كلية الطب



# **Community medicine**

Medication adherence in diabetes mellitus and self-management practice in type 2 D.M in Babylon governorate

Stage 4

مقدمة من قبل علي عبد الرضا حمد زينب محجد مهدي ابرار سعد يحيى مقتدر عبد الحسن علوان فاطمة عبد العباس جابر سجى احمد حسين محجد باقر محمود علي محجد صلاح الدين جمال علي مهدي هاشم احمد شمخي جبر زهراء ازهر عبد الحميد اية لؤي ياسر فاطمة عبدالله بخيت زهراء ضرغام جاسم بنين محجد سهر

> باشراف د. ایلاف یوسف بیرم

#### Abstract

**Background:** Type-2 diabetes mellitus and its complication are becoming more prevalent in Babylon. Evidence abound that the most important predictor of reduction of morbidity and mortality due to diabetes complication is the level of glycemic control achieved

**Objective:** The aim is to assess adherence to anti diabetic drug therapy and self management practice among type-2 diabetic patient in Babylon

Methods: A cross-sectional study was conducted among Babylon people from February 2024 to March Participants 2024. completed a Form questionnaire Google containing questions about age, gender, Monthly income.Academic achievement, When did diabetes start?,Sugar level readings, Other chronic diseases?, Types of diabetes medications used ,The extent of adherence to the medication, Reason for irregular taking of medication non-adherence .Reason for to medication, measuring blood sugar level regularly or not?, A total of 158 Babylon people either sex were enrolled in the study. 77 females and 81 males participated in the research project. Data analysis was performed

using descriptive statistics and logistic regression.

Results: Oral hypoglycemic agent were prescribed for 103(65.2%) of the patient while insulin alone in 42(26.6%) while insulin and oral hypoglycemic agent was prescribed in 13(8.2%). Only 41.8% of the patient had adequate glycemic control. The main external factors for non adherence were Multiple drug therapy (23.6%) followed by perceived side effect of drug 19.1%. Only 6.5% patient who missed their medications disclosed physician to during consultation. The knowledge and practice of critical component of diabetes self management behavior were generally low among the patient studied.

Conclusion: Majority of the patient with type 2 diabetes in Babylon are managed by OHA monotherapy glybenclamide mainly and While metformine. the current prescribing strategy do not achieve glycemic control on majority of the patient. This is due to poor adherence with the prescribed drug regimen and poor knowledge and practice of successful self-management.

## Introduction

Diabetes mellitus comprise of a group of common metabolic disorder that share the phenotype of hyperglycemia. Type-2 DM is a heterogeneous group of disorders characterized by variable degree of insulin resistance, impaired insulin secretion and increased glucose production [1].

The risk of death from cardio vascular disease is approximately three-fold for patient with type-2 diabetes; and the risk of death from all cases is increased by 75% compared to patient without diabetes [2].

Evidence abounds that the most important predictor of reduction of morbidity and mortality due to diabetes complications is the level of glycemic control achieved [3][4][5][6]. This has encouraged aggressive treatment of patients with the goal of achieving blood glucose level as close to normal as possible. Indeed, there has been a shift from **OHAs** monotherapy with to combination therapy with at least two agents often from different classes, with or without insulin; in an attempt to achieve better glycemic control, reduce incidences of acute/long term

complications and improve patient survival [5][7][8].

However, achievement of optimal glycemic control, which reduces the likelihood of diabetic complications and risk of death, is predicated on rational use of available anti-diabetic regimen, good adherence to prescribed treatments and successful self-management by patients [9][10].

Worldwide. adherence for rate medication for diabetes vary between 36 and 93%. Adherence to prescribed medication is crucial to reach metabolic control as non-adherence with blood glucose lowering or lipid lowering drug is associated with higher HbAIc and cholesterol, levels respectively. The study conducted in Netherland on refill adherence and poly pharmacy among patients with type-2 diabetes in general practice show that mean adherence with oral glucose lowering drugs is between 61 and 85%. According to this study it has become apparent an increase in the number of co-medications tends to decrease the adherence of patient with type-2 diabetes to their treatment regiments [11]. The form shows that adherence to anti diabetic drug therapy and self-management practice among type- 2 diabetics conducted in Babylon showed that about two third of patients are not adherent. Adherence to antidiabetic agents was

found to be positively associated with a decrease in HbA1c. For each 10% increase in adherence. HbA1c [13][14] decreased significantly by 0.14 to 0.16%. Nonadherence to medications among diabetic patients resulted in poor glycemic control and hence increased risk of developing chronic complications as well as hospitalization increased and mortality [15]. Accurate assessment of medication adherence is necessary for effective management of diabetes. However, there is no gold standard for such assessment although various methods have been reported in the literature [17][18].

Poor adherence to treatment of chronic disease is worldwide problem of striking magnitude. Recently, the world health organization stated that only 50% of patient diagnosed with chronic illness were fully compliant with their treatment regimen, in developing country the rate is even lower. It is undeniable that many patients' experiences difficulty in following treatment recommendations [2].

The status of patient adherence to anti diabetic therapy and self-management practice was not yet been known in Babylon. Therefore, the purpose of this study is to identify patient, medication and environmental factors associated with non-adherence to ant diabetic drug and self-management practice.

### Methods

A cross-sectional study was conducted among Babylon people from February 2024 to March 2024.

Participants were recruited from different iraqi governmental and private departments, in addition to some universities and institutes like Unvirsity of Babylon College Medicine, Hamurabi Medical College, university of baghdad college of medicine] were invited to complete a Google Form questionnaire designed to gather information on various demographic factors, lifestyle habits, eye-related and parameters. Participants were assured of the confidentiality of their responses, and participation was voluntary. Informed consent was obtained from all participants prior to completing the questionnaire.

Data analysis was performed using descriptive statistics to summarize the demographic characteristics and prevalence of type 2 DM among the participants. Logistic regression analysis was conducted to identify significant risk factors associated with type 2 DM, taking into account various demographic and lifestyle variables collected through the questionnaire.

#### Result

Patient form Review A total of 157 case notes of patient with type-2 diabetes were included. The majority 51.3% were males and 48.7% were females. The mean age was 48.3 year (SD =11.8). The most frequent comorbidity was hypertension (28.5%) obesity followed by (15.2%), coronary heart disease (5.1%), and other disease such as TB, anemia, osteoarthritis. asthma and with hyperthyroidism individual frequency of less than 3% all constituted 13.62% of the total comorbid disease, Others who do not have any other disease was (40.5%).

Oral hypoglycemic agent were prescribed for 103 (62.2%) of patients while insulin & OHA was prescribed in 42 (26.6%) of the patient. about 95(60.1%) were adhered to therapy while 63(39.9%) have not adhered to therapy. Most people measure their blood glucose level 94(59.5) while the minority 64(40.5) were not. 43(27.2%) have not complications, 35(22.2%) have renal complications, 27(17.1%) have foot ulcer,29(18.4%) have eye problems, while 24(15.1%) have other complications like (Excessive urine, Idleness,headache,fatigue,malaise and others) as showen in table 1,2 and 3.

(Table 1) Co-morbidities and Pattern of anti-diabetic drug prescribing among patients with type 2 diabetes in IRAQ.

Characteristics	Number (%)
Co-morbidities	
Hypertension	46 (29.3)
Obesity	24 (15.3)
Chronic renal failure	2 (1.3)
Ischemic heart failure	9(5.7)
Other	7 (4.5)
No co morbidities	69 (43.9)
Anti-diabetics	
Oral hypoglycemic agent	102(64.9)
(OHA)	
Insulin	42 (26.8)
Insulin + OHA	13(8.3)

(Table 2) Socio demography characteristic of type-2 diabetic patient:

Socio	Characteristic	Number
demography characteristics		(%)
Sex	Male	81 ( 51.6)
	Female	76 (48.4)

Age (in year)	< 30		55 ( 35.03 )	Being busy	35(22.3)
	30 – 40		14 ( 8.92 )	Others	52 (33.1)
	> 40		88 ( 56.05 )		
Level of	Illiterate		6 ( 3.82 )	Factor of non-adherence	
education	Primary scho	ool	17(10.82)	Side effect of drug	30(19.1)
	Secondary		30 (19.10 )	Multiple drug therapy	37(23.6)
	school			Inefficacy of drug	11(7)
	College		102 (64.96 )		
	Higher		2 (1.3 )	Easy inaccessibilityOthers	11(7)
Monthly income	None		8(5.1)		68(43.3)
(in Iraqi Dinar)	< 500		32 ( 20.38 )	Factor of non-disclosure	
	500- 1,000,0	000	58 ( 36.94 )		
	>1,000,000		59 ( 37.58)	Lack of privacy	10 (6.4)
Diabetes	1-5		56 (35.67)	Short consultation time	48(30.6)
duration				Unfriendly relation with	38(24.2)
(in year)	5-10		37 (23.57)	health professional	(1(38.8))
	>10		64 (40.76)	Other	01(38.8)
Table 3		Measure taken by patients			
Characteristics		N	umber	when having Side effects	
			(%)	No measure taken	46 (29.3)
Pattern of drug u	Ise			Omit dose sometimes	24 (15.3)
Pattern of drug u	ise	95 (	60.5)	Omit dose sometimes	24 (15.3) 87 (55.4)
Pattern of drug u Never missed	ISE	95 (	60.5)	Omit dose sometimes Inform to health professional	24 (15.3) 87 (55.4)
Pattern of drug u Never missed Missed daily	ise dose some	95 ( 48(3	60.5) 30.6)	Omit dose sometimes Inform to health professional	24 (15.3) 87 (55.4)
Pattern of drug u Never missed Missed daily d times	ise dose some	95 ( 48(3	60.5) 30.6)	Omit dose sometimes Inform to health professional Type of DMR	24 (15.3) 87 (55.4)
Pattern of drug u Never missed Missed daily d times Missed dail	ise dose some y dose	95 ( 48(3 14(8	60.5) 30.6) 3.9)	Omit dose sometimes Inform to health professional Type of DMR Bed time	24 (15.3) 87 (55.4) 12 (7.6)
Pattern of drug u Never missed Missed daily o times Missed dail frequently	ise dose some y dose	95 ( 48(3 14(8	60.5) 30.6) 3.9)	Omit dose sometimes Inform to health professional Type of DMR Bed time Mealtime	24 (15.3) 87 (55.4) 12 (7.6) 101(64.3)
Pattern of drug u Never missed Missed daily times Missed dail frequently Reason of missin	use dose some y dose 1g dose	95 ( 48(3 14(8	60.5) 30.6) 3.9)	Omit dose sometimes Inform to health professional Type of DMR Bed time Mealtime Other	24 (15.3) 87 (55.4) 12 (7.6) 101(64.3) 44 (28.02)
Pattern of drug u Never missed Missed daily o times Missed dail frequently Reason of missin Forget fullness	ise dose some y dose 1g dose	95 ( 48(3 14(8 56 (	60.5) 30.6) 3.9) 35.7)	Omit dose sometimes Inform to health professional Type of DMR Bed time Mealtime Other Knowledge of	24 (15.3) 87 (55.4) 12 (7.6) 101(64.3) 44 (28.02)
Pattern of drug u Never missed Missed daily o times Missed dail frequently Reason of missin Forget fullness Decision to omit	ise dose some y dose ig dose	95 ( 48(3 14(8 56 ( 14(8	60.5) 30.6) 3.9) 35.7) 3.9)	Omit dose sometimesInformtohealthprofessionalType of DMRBed timeMealtimeOtherKnowledgeofcomplications due to poor	24 (15.3) 87 (55.4) 12 (7.6) 101(64.3) 44 (28.02)
Pattern of drug u Never missed Missed daily times Missed dail frequently Reason of missin Forget fullness Decision to omit	ise dose some y dose ig dose	95 ( 48(3 14(8 56 ( 14(8	60.5) 30.6) 3.9) 35.7) 3.9)	Omit dose sometimesInform to health professionalType of DMRBed timeMealtimeOtherKnowledge of complications due to poor glycemic control	24 (15.3) 87 (55.4) 12 (7.6) 101(64.3) 44 (28.02)
Pattern of drug u Never missed Missed daily times Missed dail frequently Reason of missin Forget fullness Decision to omit	ise dose some ly dose ng dose	95 ( 48(3 14(8 56 ( 14(8	60.5) 30.6) 3.9) 35.7) 3.9)	Omit dose sometimes Inform to health professional Type of DMR Bed time Mealtime Other Knowledge of complications due to poor glycemic control	24 (15.3) 87 (55.4) 12 (7.6) 101(64.3) 44 (28.02)

Blindness	33(21)
Foot ulcer	27(17.2)
Kidney problem	35(22.3)
Other	62 (39.5)
Decular home block	4
Regular nome bloo	u
glucose measurement	
Yes	94 (59.9)
No	63(40.1)

#### Discussion

Presently, there is no single measure accepted as the gold standard to measure medication adherence. all commonly employed Because drawbacks. Patient methods has interviews while straight forward and inexpensive are clearly limiter by their subjective nature. Pill counts are frequently utilized, inexpensive, and can proved information about the number of pills taken. However, it is difficult determine actual to medication consumption, and patients can intentionally or unintentionally manipulate this measure. Medication refill records provide unobtrusive information regarding refills histories and can be valuable in determining gaps in therapy but this method, similar to pill counts and electronic monitors indirect and cannot confirm actual medication consumption [19].

Hypertension (28.5%) and obesity (15.2%) as the most frequent comorbidities among the patients studied. It is consistent with the established theory of metabolic syndrome, which is strongly associated with cerebrovascular disease in type- 2 diabetes [20][21]. This is in agreement with several studies [22]. The majority of the patients were on mono therapy mainly with either glibenclamide (74.3%) or metformin (25.7%) which is not consistent with recommended intensive control of blood glucose level[8,23].

The study showed that only 41.8% of the patients had adequate glycemic control and it is consistent with other studies (10) who reported adequate glycemic control in 43.8% of type -2 diabetic patients. HbA1c test was not used to monitor or assess glycemic control in any of the patient, only FPG level is used to assess and monitor glycemic control. However, HbAIc is the established gold The American diabetes standard. association position statements with standard of diabetic the care recommend that, in patient with glycemic control, at least two HbA1c test be done per year, While in patients with poor glycemic control HbA1c test should be done quarterly per year[24] and this study finding

suggest that monitoring of glycemic control in study site should be improved.

Our findings, therefore, suggest that monitoring of glycemic control among Babylon diabetics may be less than optimal and this may be a probable contributory factor to late detection of patients at risk of complications and death from poorly controlled type-2 diabetes.

The knowledge and practice of basic components of diabetes self management practices were generally among the patient studied. low However, it was significantly higher among patients who were never missed their medication and those that have excellent and good very adherence to their prescribed anti diabetic medications. These findings indeed underscore the critical role played by patient awareness and practice of diabetes self management behaviors in improving adherence to drug therapy, ensuring achievement of adequate glycemic control and minimizing the likelihood of diabetic complication.

Adherence to prescribed anti diabetic medications is crucial to reach metabolic control as non adherence with blood glucose lowering or lipid lowering drugs is associated with higher HbA1c and cholesterol levels respect lively[13]. This study revealed that adherence to anti diabetic medication in type-2 diabetic patient is problematic, only 51.3% of the patients were never missed their daily medication and (20.8% and 28.2%) of the patient have excellent and very good adherence respectively which is similar with several study

Yet this does not include the cost of other adjunctive therapy such as anti hypertensive drugs required by the majority of the patient. This is in agreement with study done in Nigeria in which around 2/3 of the nonadherence is due financial to difficulty. According to this study the average monthly cost of anti diabetic drug was \$ 22.9[10] which is much expensive as compared to this one, because in Ethiopia cost of medication is subsidized bv government for some patient. The adoption of viable cost reduction strategies such the as pooled procurement, encouraging prescribing of low price but good quality generic anti diabetic drugs and strengthening of provision of subsiding bv government and its collaborating with donor agencies may increase patient access to the needed ant diabetic medications which improve the adherence.

In this study, only 6.5% of the patients that missed their medication

claimed to have disclosed this to health care provider during consultation. The main factor cited for disclosure were. short non consultation time & lack of privacy resulting in inadequate physicianpatient interaction during consultations. This may arise due to shortage of health professional, high patient workload and poor work environment in Ethiopia.

About 56% of patients use DMR to remind them to take their prescribed medication. Meal time and bed time were the most frequently DMR used. This finding shows the patients personal dally routine plays a great role in maximizing adherence to prescribed medications. Therefore. careful identification of patientspecific routine, it use in planning patient medication regiment bv physicians during prescribing and counseling dispensing during by pharmacists should be the part of the diabetes care process. These likely to increase the chance of achieving high patient adherence with prescribed medications and subsequent optimal glycemic control.

Generally, the fact that self management practices were generally low among the patient studied indicates the need of educational empowerments is critical if successful self management is to be achieved.

This could be done with the use of a number of motivational strategies such as a scheduled home visits by designated health extension worker to evaluate and strengthen adherence with medications selfand management practices, peer-education experiences through patient and and confidential support groups; counseling by health professionals with each focusing on specific issues pertaining to their contributions to the diabetes care process.

#### Conclusion

The study have shown that majority of the patients with type 2 diabetes in Southwest Ethiopia are managed with OHA monotherapy. While the current prescribing strategy achieved glycemic control for less than half of the patients, majority are still not meeting the recommended blood glucose target. This appears mainly due to poor adherence with prescribed drug regimen and poor knowledge and practice of self management behaviors. There is a need for regular appraisal of drug prescribing and better monitoring of patient adherence with prescribed anti diabetic drugs and other diabetes self management Training practices. in learning and factors governing processes behavior are essential for all of those involved in delivery of patient care. Educational program should

recognize the wide range of learning strategies used by different peoples. The prescriber before prescribing and pharmacist before dispensing drugs for diabetic patients, he/she should negotiate about the treatment plan that the patient understands and to which he or she commits

#### References

1. Ramphal R. Endocronolgy and Methabolism. In: Fauci AS, Braunwald E, Kasper DL, editors. Harrison Principles of Internal Medicine. 17th ed. New York, NY: McGraw Hill Medical; 2008. pp. 949– 956.

2. World Health Organization, diabetes mellitus fact sheet, number 238, 2002. [Accessed August 13, 2006].

3. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999;22:27–31.

4. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–1415.

5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853.

6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformine on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet.

7. Cohen FJ, Conklin JE, Neslusan CA, Song X. Recent antihyperglyceamic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26(6):1847–1851.

8. Turner RC, Cull CA, Fright V, Holman RR for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA. 1999;281:2005– 2012.

9. Defronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med.

10. Yusuff KB, Obe O, Joseph BY. Adherence to anti diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. Pharm World Scl. 2008;30:876–883. 11. Kingh, Aubert Re, Herman W.Global burden of diabetes from 1995-2005. Diabetes Care. 1998;21:1414–1431.

12. Erasmus RT, Blanco B, Okesina AB, Gqweta Z, Matsha T. Assessment of glycemic control in stable type 2 black South African diabetics attending a peri-urban clinic. Postgrad Med J. 1999;75:603–606.

13. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care.

14. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an Indigent population. Diabetes Care. 2002;25:1015–1021

15. Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican American over a 7-year period. Diabetes Care.

16. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 17. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–284.

18. Hernshaw H, Lindenmeyer A. What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements. Diabet Med. 2006;23:720–728.

19. Vanbruggen R, Gorter K, Stolk RP. Refill adherence and poly pharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf. 2009;18:983–991.

20. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care.

21. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689.

22. Sullivan PW, Morrato EH, Ghushehyan V, et al. Obesity, inactivity and the prevalence of diabetes and diabetes-related cardiovascular co morbidities in the US, 2000–2002. Diabetes Care. 23. Chuang LM, Tsai ST, Huang BY, Tai TY. Diabcare-Asia 1998 Study Group.The status of diabetes control in Asia- a cross-sectional survey of 24,317 patients with diabetes mellitus in 1998. Diabetes Med. 2002;19:978– 985.

24. American Diabetes Association (ADA). Standard of medical care in diabetes. Diabetes Care.

25. Glasgow RE, Strycker LA, Hampson SE, Ruggiero L. Personal model beliefs and socialenvironmental barriers related to diabetes self-management. Diabetes Care. 1997;20:556–561.